Innov Clin Neurosci. 2024;21(4–6):8–10.

Funding/financial disclosures. Dr. Citrome is a consultant for AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Cerevel, Clinilabs, COMPASS, Eisai, Enteris BioPharma, HLS Therapeutics, Idorsia, INmune Bio, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Lyndra, Medavante-ProPhase, Marvin, Merck, Neurocrine, Neurelis, Novartis, Noven, Otsuka, Ovid, Praxis, Recordati, Relmada, Reviva, Sage, Sunovion, Supernus, Teva, University of Arizona, and one-off ad hoc consulting for individuals/entities conducting marketing, commercial, or scientific scoping research; is a speaker for AbbVie/Allergan, Acadia, Alkermes, Angelini, Axsome, BioXcel, Eisai, Idorsia, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Recordati, Sage, Sunovion, Takeda, Teva, and CME activities organized by medical education companies such as Medscape, NACCME, NEI, Vindico, and Universities and Professional Organizations/Societies; holds stocks (small number of shares of common stock) in Bristol-Myers Squibb, Eli Lilly, J & J, Merck, Pfizer purchased >10 years ago, stock options: Reviva; and may receive royalties/publishing income from Taylor & Francis (Editor-in-Chief, Current Medical Research and Opinion, 2022–date), Wiley (Editor-in-Chief, International Journal of Clinical Practice, through end 2019), UpToDate (reviewer), Springer Healthcare (book), Elsevier (Topic Editor, Psychiatry, Clinical Therapeutics). Dr. Mychaskiw and Ms. Cortez are employees and shareholders of Teva Pharmaceutical Industries Ltd. Dr. Sopina is a private consultant to Yorker Health. Dr. Opler and Mr. Kotak have no relevant conflicts of interest.

Dear Editor:

We thank the author of the letter to the editor for their interest in our article “Clinical Outcome Assessment Instruments in Schizophrenia: A Scoping Literature Review with a Focus on the Potential of Patient-reported Outcomes.”1

Please note that instrument types were categorized by who completes them—patient versus observer/clinician. In addition, symptoms include many different facets of schizophrenia, and cognitive impairment associated with schizophrenia can be considered a symptom. Others may wish to explore outcome instruments using different categorizations. The purpose of our work was not to describe each instrument and its scoring in granular detail, but to identify the instruments, assess who they were designed to be completed by, provide high-level psychometric and scoring details, and note whether they had minimal clinically important difference (MCID) values associated with them. 

We look forward to further contributions to the literature regarding clinically relevant and actionable outcomes so that we can continue improving the state of the art in the development of interventions for people with schizophrenia.


  1. Citrome L, Mychaskiw MA, Cortez A, et al. Clinical outcome assessment instruments in schizophrenia: a scoping literature review with a focus on the potential of patient-reported outcomes. Innov Clin Neurosci. 2023;20(4–6):14–33.

With regards,

Leslie Citrome, MD, MPH; Marko A. Mychaskiw, BSRPh, MS, PhD; Alma Cortez, BA; Mark Opler, MPH, PhD; Liza Sopina, MPH, PhD; and Sameer Kotak MS, MBA

Dr. Citrome is Clinical Professor of Psychiatry and Behavioral Sciences, New York Medical College in Valhalla, New York. Dr. Mychaskiw is Senior Director- Global Health Economics and Outcomes Research and Global Medical Affairs, Teva Branded Pharmaceutical Products R&D, Inc. in West Chester, Pennsylvania. Ms. Cortez is Director-Global Health Economics and Outcomes Research, Teva Branded Pharmaceutical Products R&D, Inc. in West Chester, Pennsylvania. Dr. Opler is Chief Research Officer, WCG MedAvante-ProPhase Inc. in New York, New York. Dr. Sopina is an independent consultant in Odense, Denmark. Mr. Kotak is with Yorker Health in Bridgewater, New Jersey.